BB
HALO icon

BB Biotech’s Halozyme HALO Stock Holding History

BB Biotech’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$134M Hold
8,322,860
– – 3.37% 12
2018
Q4 		$122M Buy
8,322,860
+75,000
+0.9% +$1.2M 3.9% 10
2018
Q3 		$150M Hold
8,247,860
– – 3.97% 10
2018
Q2 		$139M Sell
8,247,860
-272,277
-3% -$5.15M 4.02% 11
2018
Q1 		$167M Hold
8,520,137
– – 4.61% 10
2017
Q4 		$173M Sell
8,520,137
-105,914
-1% -$1.95M 4.86% 8
2017
Q3 		$150M Buy
8,626,051
+360,747
+4% +$4.89M 4.15% 10
2017
Q2 		$106M Buy
8,265,304
+515,472
+7% +$6.88M 3.24% 11
2017
Q1 		$100M Buy
7,749,832
+150,000
+2% +$1.9M 3.29% 11
2016
Q4 		$75.1M Buy
7,599,832
+220,000
+3% +$2.41M 2.78% 12
2016
Q3 		$89.1M Hold
7,379,832
– – 3.13% 12
2016
Q2 		$63.7M Hold
7,379,832
– – 2.51% 14
2016
Q1 		$69.9M Buy
7,379,832
+350,000
+5% +$3.29M 2.78% 13
2015
Q4 		$122M Buy
7,029,832
+100,000
+1% +$1.59M 3.43% 11
2015
Q3 		$93.1M Buy
6,929,832
+852,664
+14% +$17.1M 2.95% 12
2015
Q2 		$137M Sell
6,077,168
-346,202
-5% -$6.08M 3.72% 11
2015
Q1 		$91.7M Sell
6,423,370
-402,162
-6% -$5.8M 2.73% 14
2014
Q4 		$65.9M Buy
6,825,532
+395,000
+6% +$3.51M 2.13% 17
2014
Q3 		$58.5M Buy
6,430,532
+583,968
+10% +$5.56M 2.38% 14
2014
Q2 		$57.8M Buy
5,846,564
+205,000
+4% +$1.74M 2.74% 11
2014
Q1 		$71.7M Buy
5,641,564
+916,628
+19% +$13.6M 3.69% 9
2013
Q4 		$70.8M Sell
4,724,936
-791,386
-14% -$10.2M 3.78% 8
2013
Q3 		$60.9M Sell
5,516,322
-130,197
-2% -$1.08M 3.31% 9
2013
Q2 		$44.9M Buy
+5,646,519
New +$36M 3.23% 11

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

BB Biotech's HALO Position: Q1 2019 in Review

BB Biotech held its Halozyme (HALO) position steady in Q1 2019 at 8,322,860 shares worth $134M. The position accounts for 3.37% of the portfolio, ranked #12.

BB Biotech first reported a position in HALO in Q2 2013 and has held it in 24 quarters since. The position peaked at $173M in Q4 2017. 201 funds tracked by Wall St. Rank hold HALO as of Q1 2019.

  • BB Biotech held 8,322,860 shares of Halozyme worth $134M as of Q1 2019.
  • BB Biotech left its Halozyme share count unchanged in Q1 2019.
  • Halozyme made up 3.37% of BB Biotech's portfolio in Q1 2019, its #12 holding.
  • BB Biotech first reported a position in Halozyme in Q2 2013 and has held it in 24 quarters since.
  • BB Biotech's Halozyme position peaked at $173M in Q4 2017.
  • 201 funds tracked by Wall St. Rank held Halozyme as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.